Related Experiment Video

Updated: Jun 17, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Host genetic factors and treatment of hepatitis C

Jacob Nattermann1, Ludger Leifeld, Ulrich Spengler

  • 1Department of Internal Medicine I, University of Bonn, Bonn, Germany. jacob.nattermann@ukb.uni-bonn.de

Current Molecular Pharmacology
|December 22, 2009
PubMed

Insights

Hepatitis C virus (HCV) treatment response varies due to host genetics. Understanding these genetic factors, like cytokines and MHC alleles, can improve predicting outcomes and developing new therapies for chronic HCV infection.

Area of Science:

  • Hepatology
  • Virology
  • Immunogenetics

Background:

  • Hepatitis C virus (HCV) infection affects 200 million globally, risking liver cirrhosis.
  • HCV/HIV co-infection is prevalent, complicating treatment.
  • Current interferon-based therapy yields limited sustained virologic response (SVR).

Purpose of the Study:

  • To review the role of host genetic factors in HCV therapy response.
  • To explore genetic influences on predicting treatment outcomes.
  • To suggest future research directions for novel anti-HCV strategies.

Main Methods:

  • Literature review of genetic factors influencing HCV treatment.
  • Analysis of studies on cytokines, chemokines/receptors, and MHC alleles.
  • Synthesis of current data on host genetics and antiviral response.

Main Results:

  • HCV genotype and viral load are known treatment determinants.
  • Emerging evidence highlights host genetic factors impacting treatment efficacy.
  • Specific genetic markers (cytokines, chemokines, MHC) are implicated in differential responses.

Conclusions:

  • Host genetic factors are crucial for understanding and predicting HCV treatment outcomes.
  • Genetic insights can guide the development of personalized anti-HCV therapies.
  • Further research into genetic aspects is essential for advancing HCV treatment strategies.

More Related Videos

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...